EcoDrugPlus

Phospholipase A2, Membrane Associated

Ensembl ID : ENSBBBG00000004008
Gene Symbol: LOC104981060
2 Cross references
144 Possible Orthologues:

Phospholipase A2, Membrane Associated-Like

Ensembl ID : ENSBBBG00000016121
Gene Symbol: LOC104981061
2 Cross references
145 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSBBBG00000017806
Gene Symbol: GART
3 Cross references
247 Possible Orthologues:

Plasminogen

Ensembl ID : ENSBBBG00000011051
Gene Symbol: PLG
2 Cross references
269 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSBBBG00000002352
Gene Symbol: PLAT
3 Cross references
203 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSBBBG00000002716
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSBBBG00000019371
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSBBBG00000006246
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSBBBG00000019475
Gene Symbol: PDGFB
3 Cross references
263 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSBBBG00000019977
Gene Symbol: PLK1
3 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSBBBG00000008275
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSBBBG00000012265
Gene Symbol: PARP1
3 Cross references
206 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).